Edit

https://spermosens.com/
Last activity: 01.09.2026
Active
Categories: BiotechDiagnosticsFertilityIVFMedtech
Spermosens AB is a pioneering medtech company focused on improving male fertility diagnostics and IVF outcomes through its proprietary JUNO-Checked platform. The technology provides individualized analysis of sperm cell function, enabling clinics to identify the most effective treatment pathways for patients. By delivering faster, safer, and more reliable IVF workflows, Spermosens addresses a significant unmet need in reproductive medicine. Working closely with clinics and researchers, the company is building a global presence in fertility care to support millions of couples worldwide.
Mentions
85
Location: Sweden
Total raised: $512.33K

Investors 1

Funding Rounds 1

DateSeriesAmountInvestors
20.08.2026-$512.33K-

Mentions in press and media 85

DateTitleDescription
01.09.2026Bulletin from Extraordinary General Meeting in Spermosens AB (publ)Bulletin from Extraordinary General Meeting in Spermosens AB (publ) Tue, Sep 01, 2026 11:00 CET Report this content Today, September 1, 2026, the Extraordinary General Meeting was held. Below is a summary of the resolution, which was adopte...
21.08.2026Spermosens AB (publ) to Host Live Q&A Webcast on 27 August 2026Spermosens AB (publ) to Host Live Q&A Webcast on 27 August 2026 Fri, Aug 21, 2026 11:17 CET Report this content Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live Q&A we...
20.08.2026Spermosens AB (publ) INTERIM REPORT APRIL – JUNE 2026Spermosens AB (publ) INTERIM REPORT APRIL – JUNE 2026 Thu, Aug 20, 2026 08:58 CET Report this content In the second quarter of 2026, we saw recruitment into its Generation 3 clinical validation study exceed expectations, broadened partnersh...
11.08.2026Spermosens Fortifies Future with SEK 4.85M Capital InfusionSpermosens secured SEK 4.85 million through directed issues. This crucial capital fuels clinical validation for JUNO-Checked Generation 3. It propels commercialization efforts for its innovative fertility diagnostics. An Extraordinary Gener...
06.08.2026Spermosens raises approx. SEK 4.85m in directed issue and calls EGMSpermosens raises approx. SEK 4.85m in directed issue and calls EGM Thu, Aug 06, 2026 15:45 CET Report this content The Board of Directors of Spermosens AB (publ) ("Spermosens" or the "Company") has today, pursuant to th...
06.08.2026Notice of Extraordinary General Meeting in Spermosens AB (publ)Notice of Extraordinary General Meeting in Spermosens AB (publ) Thu, Aug 06, 2026 15:51 CET Report this content The shareholders of Spermosens AB (publ), reg. no. 559179-0380, are hereby invited to attend the Extraordinary General Meeting o...
06.08.2026Kallelse till extra bolagsstämma i Spermosens AB (publ)Kallelse till extra bolagsstämma i Spermosens AB (publ) Thu, Aug 06, 2026 15:50 CET Report this content Aktieägarna i Spermosens AB, org. nr. 559179-0380, kallas härmed till extra bolagsstämma tisdagen den 1 september 2026 kl. 10.00 på Medi...
21.07.2026Spermosens calls SEK 4.85 million under previously announced Capital FacilitySpermosens calls SEK 4.85 million under previously announced Capital Facility Tue, Jul 21, 2026 13:38 CET Report this content Spermosens AB (publ) ("Spermosens" or the "Company") hereby announces that the Board of Direct...
01.07.2026Spermosens provides an update on the Generation 3 clinical studySpermosens provides an update on the Generation 3 clinical study Wed, Jul 01, 2026 11:52 CET Report this content Spermosens AB (publ) (“Spermosens” or the “Company”) provides an update on the ongoing clinical study of JUNO-Checked Generatio...
18.06.2026Bulletin from Annual General Meeting in Spermosens AB (publ)Bulletin from Annual General Meeting in Spermosens AB (publ) Thu, Jun 18, 2026 12:59 CET Report this content Today, June 18, 2026, the Annual General Meeting was held. Below is a summary of the decisions that were made. All decisions were m...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In